Eikon Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	161.15	104.9	129.18	112.78
Short-Term Investments	351.03	231.07	90.93	317.63
Cash & Short-Term Investments	512.18	335.98	220.11	430.41
Cash Growth	132.69%	52.64%	-48.86%	-
Other Current Assets	17.32	12.94	7.78	6.01
Total Current Assets	529.5	348.92	227.89	436.43
Net Property, Plant & Equipment	229.13	233.86	259.13	86.88
Long-Term Investments	83.83	-	-	-
Other Long-Term Assets	8.36	11.95	4.22	2.4
Total Assets	850.83	594.73	491.24	525.71
Accounts Payable	6.01	0.68	17.58	2.19
Accrued Expenses	29.32	44.3	29.56	24.21
Current Portion of Leases	9.74	10.03	9.31	5.05
Total Current Liabilities	45.06	55.01	56.45	31.44
Long-Term Leases	245.09	247.29	193.15	26.69
Other Long-Term Liabilities	10	10	5.35	0.73
Total Long-Term Liabilities	255.09	257.29	198.5	27.42
Total Liabilities	300.16	312.3	254.95	58.86
Common Stock	0.01	-	-	0
Additional Paid-in Capital	1,554	41.48	33.01	19.75
Retained Earnings	-1,003	-920.51	-604.94	-361.13
Total Common Shareholders' Equity	550.67	-879.03	-571.93	-341.37
Minority Interest	-	1,161	808.22	808.22
Shareholders' Equity	550.67	282.44	236.29	466.85
Total Liabilities & Equity	850.83	594.73	491.24	525.71
Total Debt	254.83	257.32	202.46	31.74
Net Cash (Debt)	257.35	78.66	17.65	398.68
Net Cash Growth	227.19%	345.59%	-95.57%	-
Net Cash Per Share	4.75	27.18	7.01	196.70
Book Value	550.67	-879.03	-571.93	-341.37
Book Value Per Share	10.17	-303.75	-226.99	-168.43
Tangible Book Value	550.67	-879.03	-571.93	-341.37
Tangible Book Value Per Share	10.17	-303.75	-226.99	-168.43

SEC Filings: 10-K · 10-Q